PDCD1 and hepatocellular carcinoma: In two multicenter, phase 2 studies [3, 4] investigating the efficacy of anti-PD-1 immunotherapy in sorafenib-refractory HCC, the ORR was nearly 20%, which quadrupled that of sorafenib.